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WHEN GOOD INFORMATION TRULY MATTERS: 
PUBLIC SECTOR DECISION MAKERS ACQUIRING AND 




Since our nation’s inception, there have been a variety of 
debates about the proper boundaries between the several branches 
of U.S. federal and state governments. The argument at the heart of 
these debates centers on how best to advance the public interest. 
While each branch operates under a different set of powers, 
restraints, and processes, if this dedication to the public interest is 
internalized into the deliberations of judges, legislators, and 
bureaucrats, then the quality of the information these branch 
officials use to inform their decisions is crucial to determining how 
well the public is served. 
In the past, officials of the three branches typically depended 
on others to provide them with the bulk of the information 
necessary to complete their work. Legislators would receive 
information from lobbyists, advocates, legislative colleagues, and 
constituents. Executive branch officials heard from the same 
sources during policy formation, and because of their role in 
program administration, heard a great deal from vendors hoping to 
sell goods and services to the government as part of policy 
implementation. Judges heard from the parties arguing cases 
before them and in some cases, “friends of the court.” This 
dependency has traditionally relied on the process of advocacy, 
where both sides present their arguments to the official and the 
official as decision maker determines the relative merits of the 
                                                          
 ∗ Deputy Director, Center for Evidence-based Policy. 
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arguments in order to serve the public interest. Unfortunately, in 
this model there is no guarantee that the information presented to 
these officials by the respective advocates is of good quality. It is 
conceivable that both sides, in their push to prevail, will present 
only the information that is most supportive of their preferred 
policy or helpful to their case and most damaging to their 
opponents’, without providing a clear view of the quality or 
thoroughness of the information used. In policy formation and 
implementation, this problem often manifests itself through 
advocates emphasizing emotional examples that may not be 
representative of the broader implications of an issue or through 
vendors claiming to have a study that shows that their product is 
superior while conveniently forgetting to mention multiple other 
studies that do not. Furthermore, judges are accustomed to having 
the parties before them provide information selected not for its 
thoroughness or factual strength but for its ability to support their 
case. 
This paper explores a trend among public officials to become 
more active in gathering the information they use to inform their 
decisions. It is a trend in which executive branch officials seek and 
increasingly commission independent research to balance the 
marketing information supplied by vendors of goods and services, 
be they road contractors or cardiologists. This is a trend that finds 
legislators funding nonpartisan research and participating in 
networking and training to enhance their ability to access and 
interpret relevant high quality information; a trend in which 
members of the judicial branch appoint their own experts to 
provide information on highly technical subjects, and attend 
training on how to better assimilate scientific information into their 
decision making; a trend that is greatly enhancing the ability of 
officials throughout all branches of government to make informed 
policy decisions. 
This paper is based on the author’s personal experience as 
senior staff in legislative leadership, a governor’s office, and as 
deputy director of the Center for Evidenced-based Policy, an 
academic center dedicated to linking high quality research to the 
practice of policy making. Part I introduces a research process 
known as a “systematic review” that is widely seen as the gold 
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standard of clinical research. Part II explores the Drug 
Effectiveness Review Project (DERP) as an example of using 
systematic reviews to support public policy decisions. DERP is a 
collaboration of fifteen states and two other organizations that 
commissions and uses systematic reviews of global research to 
inform drug purchasing decisions in their Medicaid, corrections, 
workers’ compensation, general healthcare, and employee benefits 
programs. Finally, the paper sets out examples of the criticisms 
being leveled at DERP and responses to those criticisms in order to 
give public officials a sense of the tone and substance of the debate 
that DERP has engendered. 
 
I. SYSTEMATIC REVIEWS AS A DECISION MAKING TOOL FOR PUBLIC 
OFFICIALS 
By their nature, public policy makers and the courts deal with 
very serious questions. It is understandable that those who work in 
these fields would covet information that would make their 
decisions unerringly correct. While the science available for 
supporting decisions in health policy has improved substantially, 
these improvements do not signal the approach of a time when 
definitive information is available to settle every question. The 
improvements have not created a “silver bullet” for each vexing 
issue but rather a useful tool that in some cases provides clear 
direction or aids in simply ruling out unhelpful courses. It 
behooves anyone involved in health policy issues to understand 
how to access and evaluate the specific information available for 
any given question. 
One of the greatest advances in making research more useful to 
policy makers is the growing production and use of systematic 
reviews (SR) and, when appropriate, the meta-analysis of clinical 
evidence in healthcare. A well prepared SR allows one to have far 
greater confidence that the level of global knowledge on a given 
set of questions is accurately represented.1 This is because the SR 
                                                          
1 DRUG EFFECTIVENESS REVIEW PROJECT Home Page, at 
http://www.ohsu.edu/drugeffectiveness/methods/index.htm [hereinafter DERP]. 
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conscientiously searches for all available relevant evidence, 
rigorously analyzes its quality, and then synthesizes the best 
evidence in a manner that communicates the sum of that 
knowledge. 
Of course, any public official worthy of the title hopes for 
research that provides “road to Damascus” clarity on the issue of 
the moment. While this is possible, it is more likely that the 
assistance provided even by a SR will be more nuanced. Often, 
officials must settle for the “best available” evidence at the time, 
which may include gaps and inconsistencies. Even less directly 
helpful can be the knowledge that there is no good evidence 
available to address a given issue. However, even this modest 
knowledge can be useful. Considering that in public policy, a 
failure to make a decision constitutes a decision to maintain the 
status quo, understanding the best available evidence can help a 
public sector decision maker judge the relative risk of selecting 
between the status quo and a possible initiative. For policy makers, 
judges, and jurors, understanding that there is no good evidence 
can provide a key counter to the claims of advocates expressing 
certainty in the merit of their position, product, or client. 
II. DRUG EFFECTIVENESS REVIEW PROJECT: POLICY MAKERS 
DIRECTLY ACQUIRING AND USING RESEARCH 
On average, healthcare and education are the two largest 
expenditures in state budgets. Among the states, Medicaid 
expenditures now exceed expenditures on primary and secondary 
education.2 One of the fastest growing segments of Medicaid 
spending is for prescription drugs. States are working diligently to 
ensure that they receive value for the dollars they spend. One 
strategy includes promulgating preferred drug lists, a process in 
which the state creates incentives for patients to use drugs that are 
similar in effectiveness but lower in cost. The key to successfully 
using a preferred drug list is making sure that the preferred drug is 
                                                          
2 NATIONAL GOVERNOR’S ASSOCIATION AND NATIONAL ASSOCIATION OF 
STATE BUDGET OFFICERS, THE FISCAL SURVEY OF THE STATES: JULY 2005 4, 
(June 2005) available at http://www.nasbo.org/Publications/fiscalsurvey/ 
fsspring2005.pdf. 
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of equal or greater effectiveness than other drugs used to treat a 
given condition. To ensure that they have the best possible 
information on which to base their selection of preferred drugs, 
fifteen states (and two other organizations) have formed an 
international collaboration called the Drug Effectiveness Review 
Project (DERP). 
DERP provides systematic evidence-based reviews of the 
comparative efficacy/effectiveness and safety of drugs in twenty-
six of the most commonly prescribed drug classes. The project is 
funded by multiple public and private entities, including fifteen 
states, the California Healthcare Foundation, and the Canadian 
Coordinating Office for Health Technology Assessment. In 
governing the project, these participating entities determine and 
prioritize the classes to be reviewed and the content of the research 
questions. When a systematic review is completed, each member 
organization makes its own decision on whether and how the 
results will inform the policies for which it is responsible. 
The project is administered by the Center for Evidence-based 
Policy (CEP) at Oregon Health & Science University (OHSU).3 
The CEP supports the project’s governance, contracting, and 
communications processes. 
The reports are produced by a consortium of Evidence-based 
Practice Centers (EPCs), which are research organizations that are 
competitively selected by the federal Agency for Healthcare 
Research and Quality (AHRQ).4 The research process is 
coordinated by the Oregon EPC at OHSU. The Oregon EPC is 
independent and separate from the CEP at OHSU.5 
                                                          
3 OREGON HEALTH AND SCIENCE UNIVERSITY, 
http://www.ohsu.edu/policycenter (last visited Dec. 2005). Details regarding 
DERP, including current drug class reports, are available to the public at the 
project website http://www.ohsu.edu/drugeffectiveness. 
4 EVIDENCE-BASED PRACTICE CENTERS, http://www.ahrq.gov/clinic/epc 
(last visited Dec. 2005). Other than commissioning research with these Centers, 
DERP has no relationship with AHRQ. 
5 DERP, supra note 1. 
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A. DERP Process 
The entire DERP process is fully transparent and patterned 
after the systematic review process followed by AHRQ. Public 
input is solicited and considered multiple times for each report. All 
sources of information are fully disclosed, and investigators are 
prohibited from having any economic interests in the subjects they 
study. 
The DERP process begins with the creation of a set of research 
questions. These key questions are formed through an iterative 
process in which interested parties exchange feedback in public 
meetings held in participating states and researchers and policy 
makers consult with one another directly in order to create a first 
draft. This draft is then posted on the project web site and 
comments are solicited from the industry and the public at large. 
Once public comment has been received and considered, the policy 
makers representing the organizations participating in the project 
agree on the final form of the key questions. Because the questions 
define the scope and focus of the report, the drugs in the class, 
populations of interest, diseases affected by the drugs, outcomes of 
interest, and the most appropriate types of studies to be included in 
the report, creating these questions can take several months. 
When the key questions are finalized, they are sent to each 
pharmaceutical manufacturer in the United States and Canada 
along with a request for any research evidence the manufacturer is 
willing to share that is relevant to the questions. Informational 
dossiers submitted by the drug companies in response to this 
request are forwarded to the researchers for their consideration as 
they compile the report. Five to ten percent of the citations in a 
typical evidence report come as a result of these submissions.6 
Dossiers submitted by the companies are available to the public 
upon request. 
As dossiers are gathered, the researchers begin their own 
search for clinical evidence. They routinely search the major 
clinical data bases such as EMBASE, MedLINE, and the Cochrane 
                                                          
6 Estimate provided by John Santa, MD, MPH, Medical Director for DERP. 
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Registries of Clinical Trials and Systematic Reviews.7 In addition, 
the bibliographies of studies considered relevant are also searched 
for citations not found through the electronic databases. 
Studies identified as potentially useful are then read in detail to 
determine if they are relevant to the key questions. If they are 
found to be relevant, the design and execution of the study is 
carefully evaluated and those studies with flawed methodology are 
then removed from consideration. Evaluating the quality of the 
relevant research is a critical step because much of the research 
available to compare similar drugs is of poor quality. Even 
randomized controlled trials, regarded as the gold standard of 
clinical research, can be poorly designed, executed, or reported in 
ways that leave consumers and decision makers with a misleading 
view of reality. Common shortcomings in the research and the 
reporting of such research are succinctly catalogued by David 
Sackett and Andrew Oxman and include but are not limited to: 
• run in periods where only patients previously 
determined to tolerate the drug are included in the trial 
thereby underestimating the adverse events associated 
with the drug in the trial; 
• high dose/low dose comparisons where the drug of the 
company sponsoring the study is administered at a high 
dose while a competitor’s drug is administered at a low 
dose thus increasing the chance that the high dose drug 
will show a greater response; 
• multiple study analyses (meta-analyses) that include 
only studies that show a favorable result and 
eliminating studies that show indeterminate or 
unfavorable findings; 
• when the overall research is indeterminate, the 
performance of subgroup analyses until favorable 
results can be found then report only the favorable 
results and ignore the rest.8 
                                                          
7 G. Gartlehner et al., Drug Class Review on Second Generation 
Antidepressants 9, 9-10 (2006), at http://www.ohsu.edu/drugeffectiveness/ 
reports/documents/Antidepressants%20Final%20Report%20Update%202.pdf. 
8 David L. Sackett & Andrew D. Oxman, HARLOT plc: An Amalgamation 
of the World’s Two Oldest Professions, 327 BRITISH MEDICAL JOURNAL 1442, 
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After carefully analyzing studies that are potentially useful, 
studies found to be of good quality are then synthesized into a draft 
report which is both posted for public comment on the project’s 
web site and sent out to peer reviewers who have experience in 
both evaluating evidence and with the subject area addressed by 
the drug class under review. Once received, the public and peer 
review comments are considered in detail. Legitimate concerns 
raised by either the public or the peer reviewers that fit the scope 
of the report are addressed in the final draft, which is posted on the 
project website in the public domain.9 
DERP does not consider the cost of the drugs in its reports nor 
does it recommend a preferred drug in a class. The manner in 
which a report is used (or not used) is entirely up to the 
participating organization and the policies in their jurisdictions. 
These uses range from creating prescriber education materials 
based on the reports, to evaluating the clinical advice given by a 
pharmacy benefits manager, to being the primary source of clinical 
information for a preferred drug list pharmacy and therapeutics 
committee. States that use the reports to inform their pharmacy and 
therapeutics committees have open public meetings for decision 
making, and provide opportunities for public testimony on the 
policies under consideration.10 
Completed reports are eventually updated as new drugs, new 
evidence, and new issues are identified and assessed in the context 
of previous evidence. For example, the Statin drug class report has 
been updated four times since the original report was completed in 
2002. The report for atypical antipsychotic medication is currently 
being updated in order to assess the importance of observational 
trials and a recent large comparative trial. 
The experience of public decision makers in the  
DERP project is illustrative of some of the advantages, 
disadvantages, and challenges such an approach brings. One of the 
greatest advantages of using systematic reviews in this way is that 
                                                          
1442-1445 (2003), available at http://www.urmc.rochester.edu/ 
smd/student/defib/pdf/BMJ_Harlot.pdf. 
9 DERP, supra note 1. 
10 Information on the decision making bodies of each state participating in 
DERP are available on the Project website. Id. 
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decision makers have better information at their disposal on the 
comparative effectiveness and safety of the medications they are 
buying than other purchasers or even their suppliers. This allows 
them to have confidence that the drugs they select are high quality 
and that the savings they achieve by preferring one drug over 
another do not compromise the quality of the healthcare delivered 
to their patients. 
The process of creating a systematic review can pose many 
challenges. First, it can take a significant amount of time to 
complete. While most states would prefer to receive the 
information on drug classes in the space of just a few months in 
order to make decisions more quickly, on average, these 
comparative drug class studies take between eight and ten months 
to complete. Overall, the DERP project has taken approximately 
three years to complete twenty-five original reviews. Moreover, 
systematic reviews must also be updated on a regular basis. 
Depending on the amount of research underway in a given class, 
this may need to be done annually and in some cases even more 
frequently. 
In addition to being time consuming, systematic reviews can 
also be expensive. For instance, the first casses reviewed by DERP 
averaged $110,000 per report. Also, in their completed form, SRs 
are highly technical documents, making translation for use in the 
policy process laborious as well. However, these challenges can be 
overcome through planning, patience, expense sharing among 
interested parties, and careful summation of the studies that allow 
officials and the public to accurately understand the essence of the 
research. 
Unfortunately, as one might expect, those threatened by the use 
of this research have attempted to discredit the research or limit its 
use. These efforts have run a continuum from blatant 
misrepresentation to reasonable questions of methodology that will 
require ongoing deliberation within the research and policy 
communities. The DERP experience can give public officials a 
sense of the tone and substance of the debate they will experience 
even when they are using what is demonstrably the best available 
information to inform their work. 
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B. Critisim of DERP Reports 
The use of DERP reports raises several important concerns. 
However, when judging DERP’s approach, or any other attempt to 
use systematic reviews to inform public decisions, it is important 
to compare it to the other information development and 
dissemination strategies currently used in government and 
industry. Recognizing this context is important because new 
initiatives are often judged in comparison to a hypothetical ideal 
rather than against the current approaches they seek to change. 
This allows defenders of the status quo to argue against 
constructive change without explicitly defending the status quo. 
Thus, critics will profess support for evidence based medicine 
while they belittle DERP because its reports do not take into 
account the infinite variability of individuals. Of course, no study 
using existing technology could ever provide that level of detail, so 
the fact that DERP is a marked improvement over what is currently 
available to help policy makers, consumers, and providers decide 
which drugs are better overall is denigrated because it does not 
provide perfect information for every patient.11 The common 
criticisms of DERP and their implications for other public sector 
decision makers using similar research to inform their decisions 
are addressed in detail below. 
1. DERP Conflicts with the Principles of Evidence-Based Medicine 
The criticism that DERP conflicts with the principles of 
evidence-based medicine almost always relies on selective 
reference to Dr. David Sackett, an international authority on 
evidence-based medicine. Critics cite Dr. Sackett’s article from 
1996 as support for their claim that all forms of information, 
including observational studies and patient preference, should be 
used in DERP’s assessment of the efficacy or effectiveness of the 
drugs it studies.12 These criticisms ignore that in that same article, 
                                                          
11 MENTAL HEALTH ASSOCIATION IN CALIFORNIA, Background, 
http://www.mhac.org/advocacy/alliance_background.cfm. 
12 David L. Sackett et al., Evidence Based Medicine: What It Is and What It 
Isn’t, 312 BRITISH MEDICAL JOURNAL 71, 71-72 (1996). 
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Sackett went on to say: 
It is when asking questions about therapy that we should try 
to avoid the non-experimental approaches, since these 
routinely lead to false-positive conclusions about efficacy. 
Because the randomized trial, and especially the systematic 
review of several randomized trials, is so much more likely 
to inform us and so much less likely to mislead us, it has 
become the gold standard for judging whether a treatment 
does more good than harm.13 
The systematic review of all available randomized controlled 
trials (RCTs) called for by Sackett is exactly what DERP provides. 
This is in sharp contrast to the kind of information generally used 
as the basis for establishing comparative efficacy in the industry. 
There is no evidence that pharmaceutical companies conduct 
systematic comparative reviews of the drug classes. Many 
purchasers rely on cost effectiveness analyses that begin with a 
bare minimum of evidence and a consultant’s opinion rather than a 
synthesis of the entire relevant evidence. Additionally, most 
purchasers, insurers, and pharmacy benefits managers consider the 
information they rely on for their decisions to be proprietary and 
therefore secret, even if they profess to be “evidence-based.” Thus, 
there is no way to judge the quality or objectivity of the 
information used. It appears that DERP’s standard of evidence is 
of higher quality than that of its primary critics. 
More fundamentally, the question should not be whether DERP 
or any information effort is consistent with anyone’s assertion of 
what is or is not evidence-based medicine. Rather, the truly 
important question is whether decisions to wisely purchase or 
prescribe drugs are helped or hindered by properly executed 
systematic reviews comparing drugs within classes. Clearly, the 
appropriate use of these reviews can be of enormous help to 
decision makers. This is especially true when the alternative is to 
depend on a model of research and information dissemination that 
has at its core the selective use of information to maximize market 
share. Similarly, the practice of evidence-based medicine could be 
helped substantially if the healthcare industry as a whole shared 
                                                          
13 Id. 
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DERP’s commitment to systematically reviewing all high quality 
evidence, and to public participation and full disclosure of all 
research results. 
2. DERP is Not Sufficiently Transparent and Inclusive 
The critical elements of the DERP processkey questions, 
research considered, industry dossiers, public comments, draft 
reports, final reports, local decision making processesare 
transparent and inclusive: they are either posted on the DERP 
website or available on request.14 The current participants in DERP 
all have public processes in which the DERP reports are available 
or presented in public. 
Again, the DERP process compares favorably to that used 
generally by healthcare purchasers, providers, and manufacturers. 
In fact, the overall information available to practitioners and 
consumers could be improved substantially if similar standards of 
transparency and inclusiveness were adopted by drug and device 
manufacturers, pharmacy benefits managers, insurers, and the 
creators of practice guidelines. 
3. DERP Defines Evidence Too Narrowly 
This criticism seeks to discredit DERP because of its emphasis 
on randomized controlled trials (RCTs) in determining 
comparative efficacy/effectiveness.15 However, making the breadth 
of the evidence the primary indicator of its quality is a mistake. A 
more useful approach is to determine whether the evidence in 
question is appropriate for the use to which it is put. 
DERP relies primarily on RCTs to determine the 
efficacy/effectiveness of medications under review because, as 
Sackett stated, they are much less likely to mislead us than other 
forms of research that are less rigorous in their efforts to eliminate 
                                                          
14 DERP Methods, http://www.ohsu.edu/drugeffectiveness/methods/ 
index.htm. 
15 ISPOR HEALTH SCIENCE POLICY COUNCIL, WHERE DOES OUTCOMES 
RESEARCH FIT INTO EVIDENCE-BASED HEALTHCARE DECISION-MAKING?, 
available at http://www.ispor.org/councils/Decision_making.asp. 
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bias and confounding factors from their work. To minimize the 
potential for bias, RCTs require random assignment of study 
participants to either the group receiving the experimental 
intervention (active) or the group not receiving the experimental 
intervention (control). Those who evaluate the effects of the 
intervention must be blind to whether the subject was in the active 
or control arm of the study. Well-prepared RCTs are almost always 
conducted in highly controlled settings with carefully selected 
participants who have similar characteristics in order to make sure 
the methodology is carefully carried out, and to attempt to make 
certain that changes observed are actually due to the treatment and 
not to chance, subconscious decisions made by researchers, or an 
underlying characteristic of the subject. The highly controlled 
nature of these trials is very effective at removing bias from the 
study, but legitimate questions remain about how readily they can 
be generalized to a community care setting in much more 
complicated patients. 
To address some of these concerns, researchers are developing 
large scale community based trials that still have randomization 
and blinding in their procedures, but reflect more closely the 
results one could expect in the real world. DERP recognizes that 
well-prepared large scale practical controlled trials comparing the 
effectiveness of these drugs in community practice settings can be 
better than RCTs done in a research setting, and we use them 
whenever they are available.16 Unfortunately, such effectiveness 
studies are rare and the fact that our inclusive search strategy finds 
so few of them highlights a flaw in the priority setting among the 
major funders of comparative drug research. 
In addition, while DERP gives preference to well done RCTs 
when assessing efficacy/effectiveness, it also routinely considers 
observational studies when evaluating adverse events because 
these studies often include larger populations and are of longer 
duration than RCTs. This addresses the problem posed by the fact 
that RCTs are often too short and the sample size too small to find 
                                                          
16 Sean R. Tunis et al., Practical Clinical Trials: Increasing the Value of 
Clinical Research for Decision Making in Clinical and Health Policy, 290 
JAMA 1624, 1624-32 (2003). 
GIBSON MACROED CORRECTED 07-30-06.DOC 7/30/2006 12:33 PM 
564 JOURNAL OF LAW AND POLICY 
adverse events associated with longer term and broader use. This is 
especially important given the number of medications now 
designed to be taken for the remainder of a patient’s life. 
These issues of breadth versus quality of evidence will 
continue to be a focus of intense discussion because at present 
there is no consensus among clinicians, researchers, or decision-
makers about the validity of observational studies for assessing the 
comparative effectiveness of different drugs. The most common 
comparative observational studies—retrospective designs such as 
the case-control study, and prospective designs such as cohort 
studies—were designed to test hypotheses about causal agents in 
the epidemiology of disease. Their suitability for drawing valid 
conclusions about comparative efficacy or effectiveness in clinical 
practice has not yet been established. 
To advance this discussion, DERP is testing whether 
observational studies are useful in determining efficacy or 
effectiveness by investing resources to evaluate the quality of 
evidence generated by observational studies of atypical anti-
psychotic medications, ADHD medications, targeted immune 
modulators, and inhaled corticosteroids. This effort, along with 
initiatives underway by AHRQ related to the Medicare 
Modernization Act,17 should shed additional light on whether they 
are useful and if so, what methods are essential to that utility. 
Even given this ongoing debate, the DERP approach appears to 
compare favorably to the common practice of using narrow 
placebo controlled efficacy trials as the basis for direct-to-
consumer and physician-focused advertising campaigns. It is also 
clearly superior to the practice of manipulating evidence related to 
a product by suppressing research that does not support the desired 
point of view or by only releasing partial results from major 
studies.18 The willingness of the DERP project to use its limited 
resources in a good faith effort to analyze the appropriate use of 
                                                          
17 Medicare Prescription Drug, Improvement, and Modernization Act of 
2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003). See also 
http://www.effectivehealthcare.ahrq.gov/aboutUs/aboutUs.cfm#MMA. 
18 P. Juni et al, Are Selective COX 2 Inhibitors Superior to Traditional Non 
Steroidal Anti-inflammatory Drugs, 324 BRITISH MEDICAL JOURNAL 1287, 
1287-1288 (2002). 
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observational studies and to disclose those results publicly speaks 
to the project’s commitment to the public interest. 
4. DERP Findings Do Not Sufficiently Address Variations Among 
Subpopulations19 
In every DERP review, one of the key questions always 
focuses on what the evidence shows about any differential impact 
of a medication on a given subpopulation, and whether that 
population is defined by gender, race, age or ethnicity. DERP 
reports only reach conclusions regarding subpopulations that are 
supported by the evidence. Unfortunately DERP’s research has 
found that there is a real shortage of good quality studies of 
subpopulations. This lack of information is largely the result of the 
decisions made by the funders of primary research, rather than 
DERP. 
Nonetheless, this raises the question of whether DERP 
participants should limit the use of evidence from RCTs if studies 
do not focus specifically on a given subpopulation and should 
instead consider less rigorously designed studies, if available, on 
that subpopulation. Those who advocate for this position would 
seem to argue for adopting a lower standard of evidence for such 
groups by ignoring high quality information developed in other 
groups until more rigorous studies of the precise group in question 
can be completed. Additional study and discussion should be 
undertaken within the research and policy communities to 
determine if the public interest is better served if the treatment for 
subpopulations is based on lower quality studies that include them 
rather than high quality studies that look at a general population. 
Few dispute, however, that the major funders of research 
(including the pharmaceutical industry) should design and fund 
more high quality studies that directly consider the effects of 
treatments on subpopulations. 
5. DERP Confuses the Absence of Evidence for Evidence of No 
                                                          
19 AGENCY FOR HEALTHCARE RESEARCH AND QUALITY Info Page, 
http//www.mhac.org/advocacy/alliance_background.cfm. 
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Difference Among Drugs 
A careful reading of all of the DERP reports will show that 
DERP never claims that the lack of evidence of a difference should 
be interpreted as evidence that there is no difference. DERP reports 
specify what evidence exists and what evidence is lacking, and it is 
up to the purchasers who use the reports to decide if they are 
willing to pay more for medications that have no evidence of 
superiority. 
Concerns have been expressed that some DERP participants 
make value decisions in the absence of evidence. The systematic 
review of long acting narcotics used for the relief of chronic pain, 
for example, shows that there are no fair or good quality 
randomized controlled trials comparing these drugs to each other. 
While there is no good quality evidence comparing the 
effectiveness of these drugs, there are substantial price differences 
among them. So, the policy question raised by this lack of 
evidence coupled with a significant difference in price focuses on 
what constitutes good stewardship of taxpayer dollars and whether 
public payers for health services should insist on some credible 
clinical evidence before paying a significantly higher price for a 
comparable medication. 
6. DERP is Focused Solely On Cost and Should Be Rejected 
Because it May Be Misused and Do Harm to Vulnerable Persons 
A classic example of this criticism is an article in The Medical 
Herald.20 In its April 2005 edition, the newspaper headlined the 
story “States Misuse Evidence-Based Medicine.” As reported, 
several physicians and the chairman of the board at Pfizer 
Pharmaceuticals roundly condemned using medical evidence in 
policy formulation as a danger to vulnerable populations, 
especially racial minorities. The article supports the use of 
evidence in a clinical setting by a single practitioner in consultation 
with a patient but alleges, for example, that “minorities will be 
                                                          
20 Tom Toolen, States Misuse Evidence-Based Medicine, THE MEDICAL 
HERALD, Apr. 2005 at 1. 
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hardest hit by faulty analysis by untrained government bureaucrats, 
with many being denied life-saving drugs because they cost too 
much.”21 
While the article is full of numerous suggestions that using 
evidence in Medicaid policy decisions, especially decisions to 
control costs, will result in denial of beneficial services to 
vulnerable populations, there is not one example cited that 
documents this. Curiously, the authors focus their worries on 
programs that are using high quality evidence, rather than those 
programs that ignore evidence and use draconian measures such as 
limiting the number of prescriptions Medicaid recipients receive 
regardless of their condition or the effectiveness of additional 
prescriptions to treat them. 
The article, written without quoting one Medicaid official or 
representative of DERP, seems to take the position that working to 
control the cost of Medicaid is optional. It conveniently ignores the 
enormous cost increases recently seen in Medicaid, the consensus 
that they are unsustainable, and the role that drug expenditures 
play in those increases. The article conveniently sidesteps the 
question of whether it is better to use or ignore good quality 
evidence when taking unavoidable steps required to control costs 
in Medicaid. The parties quoted in the article seem to argue that it 
is permissible to deny persons access to life saving medications by 
pricing them at a level that is unaffordable to millions of 
Americans while it is unconscionable for state governments to try 
to use evidence to make sure that their polices are clinically sound. 
CONCLUSION 
Public sector decision makers in all branches of government 
need consistently good information to inform the important 
decisions they make. Legislators and executive branch officials 
need such information in policy formation and implementation, 
and the judiciary needs it to determine if the law is being followed. 
Research that is directly applicable to public sector healthcare 
decisions is improving and increasing in prevalence. This trend is 
                                                          
21 Id. at 25. 
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supported by a more aggressive acquisition of good quality 
research by public sector decision makers. The barriers to 
increasing this acquisition even further can be reduced by a wider 
recognition of its utility that increases demand for it, by 
jurisdictions sharing the costs of directly commissioning research 
relevant to policy, and by focusing the research on questions that 
have immediate relevance to the public interest. The public interest 
is well served when good quality research is used to inform public 
sector decisions, and by a vigorous debate about what defines good 
quality research and decision making processes for these purposes. 
 
 
